{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:32:38Z","timestamp":1793082758435,"version":"4.5.0"},"reference-count":19,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"unspecified","delay-in-days":135,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anxiety disorders, characterized by excessive fear and behavioral disturbances, are among the most prevalent psychiatric conditions, yet treatment options remain suboptimal for many patients. Clonidine, an alpha-2 adrenergic receptor agonist, has shown potential anxiolytic effects and may address treatment-resistant cases. This review explores the efficacy, safety, and mechanism of clonidine as a pharmacological option for anxiety disorders, with emphasis on its role in modulating noradrenergic dysfunction and its potential synergistic effects with existing therapies. A literature review was conducted to evaluate clinical studies, case reports, and comparative trials on clonidine\u2019s use in anxiety disorders, focusing on its pharmacological profile, efficacy, and tolerability. Evidence suggests clonidine may reduce anxiety symptoms, particularly in treatment-resistant cases and specific populations, such as pediatric patients and those with comorbid psychiatric disorders. Its mechanism involves modulating norepinephrine release and glutamatergic pathways. Case studies and small trials highlight its potential in reducing cognitive symptoms of anxiety, but inconsistencies in efficacy and side effects, including sedation and hypotension, were noted. Comparative studies suggest clonidine may have similar efficacy to SSRIs in some cases but lack large-scale validation. Clonidine presents as a promising pharmacotherapeutic option for anxiety disorders, particularly in cases resistant to conventional treatments or in patients with contraindications to other typical medications. Its mechanism of action, tolerability, and potential synergistic effects with existing therapies underscore the need for continued exploration and clinical trials to establish its optimal role in anxiety disorder management.<\/jats:p>","DOI":"10.1017\/s1092852925100266","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:55:50Z","timestamp":1747371350000},"source":"Crossref","is-referenced-by-count":6,"title":["Exploring the potential benefits of clonidine for anxiety disorders"],"prefix":"10.1017","volume":"30","author":[{"given":"Esha","family":"Aneja B.S.","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03h0d2228","id-type":"ROR","asserted-by":"publisher"}],"name":"California Northstate University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soojae","family":"Hollowell","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040kfrw16","id-type":"ROR","asserted-by":"publisher"}],"name":"SUNY Upstate Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schwartz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040kfrw16","id-type":"ROR","asserted-by":"publisher"}],"name":"SUNY Upstate Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"S1092852925100266_r9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03563.x"},{"key":"S1092852925100266_r12","volume-title":"Clonidine for the Treatment of Psychiatric Conditions and Symptoms: A Review of Clinical Effectiveness, Safety, and Guidelines","author":"Chiu","year":"2018"},{"key":"S1092852925100266_r3","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2016.1173545"},{"key":"S1092852925100266_r14","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1981.01780360094011"},{"key":"S1092852925100266_r4","doi-asserted-by":"publisher","DOI":"10.1002\/da.20337"},{"key":"S1092852925100266_r19","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105059253"},{"key":"S1092852925100266_r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2013.06.006"},{"key":"S1092852925100266_r17","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810260065010"},{"key":"S1092852925100266_r15","doi-asserted-by":"publisher","DOI":"10.1111\/pan.14740"},{"key":"S1092852925100266_r18","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00246-2"},{"key":"S1092852925100266_r6","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244432"},{"key":"S1092852925100266_r7","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820080045007"},{"key":"S1092852925100266_r1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow"},{"key":"S1092852925100266_r10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00755"},{"key":"S1092852925100266_r13","doi-asserted-by":"publisher","DOI":"10.1159\/000446441"},{"key":"S1092852925100266_r5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.749"},{"key":"S1092852925100266_r8","first-page":"941","article-title":"Neurobiology of anxiety disorders and implications for treatment","volume":"73","author":"Garakani","year":"2006","journal-title":"Mt Sinai J Med."},{"key":"S1092852925100266_r11","volume-title":"StatPearls","author":"Yasaei","year":"2023"},{"key":"S1092852925100266_r16","first-page":"e14920","article-title":"The use of clonidine in the treatment of debilitating obsessive-compulsive behaviors comorbid with depression and post-traumatic stress disorder: a case report","volume":"13","author":"Sarangi","year":"2021","journal-title":"Cureus."}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852925100266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:52:14Z","timestamp":1759848734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852925100266\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"alternative-id":["S1092852925100266"],"URL":"https:\/\/doi.org\/10.1017\/s1092852925100266","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e43"}}